{
    "clinical_study": {
        "@rank": "129257", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "1.2 mg liraglutide sc. (single-dose)"
            }, 
            {
                "arm_group_label": "Placebo-liraglutide", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo liraglutide sc. (single-dose)"
            }
        ], 
        "brief_summary": {
            "textblock": "Recent studies in rodents show that glucagon-like peptide-1 (GLP-1) analogues protect\n      against diabetic nephropathy. We hypothesise that this is also the case in humans. This\n      study will investigate the short-term effect of liraglutide (GLP-1 analogue) on the kidneys\n      in type 2 diabetic patients. Impact on basic kidney physiological will be determined and\n      kidney injury markers will be measured as surrogate parameters of kidney protection."
        }, 
        "brief_title": "Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities.\n\n          -  Male gender\n\n          -  T2DM, diagnosed according to international guidelines\n\n          -  Age 20-60 years, both included\n\n          -  Body Mass Index (BMI): 20-32 kg/m2, both included\n\n          -  Metformin treatment\n\n          -  Albumin/creatinine ratio <25 mg/mmol\n\n        Exclusion Criteria:\n\n          -  Known or suspected allergy to trial product or related products\n\n          -  Previous participation in this trial\n\n          -  Previous treatment with GLP-1 analogues or DPP-4 inhibitors\n\n          -  Current treatment with any antidiabetic drug other than metformin\n\n          -  Poorly regulated glycemic control (HbA1c > 8%)\n\n          -  Impaired kidney function: estimated GFR < 70ml/min\n\n          -  Impaired liver function: liver parameters exceed 2 times upper normal limit\n\n          -  Subjects with active malignancy\n\n          -  Severe cardiac insufficiency classified according to NYHA III-IV\n\n          -  Unstable angina pectoris, acute myocardial infarction (AMI) within the last 12 months\n\n          -  Severe, uncontrolled hypertension: sitting blood pressure (BP) > 180/110 mmHg\n\n          -  Antihypertensive treatment consisting of more than two different pharmaceutical\n             products\n\n          -  Symptoms related to benign prostate hyperplasia\n\n          -  Claustrophobia\n\n          -  Any metal body implants\n\n          -  History of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine\n             neoplasia syndrome type 2\n\n          -  Personal or family history of medullary thyroid carcinoma\n\n          -  Any diseases judged by the investigator that could affect the trial\n\n          -  Any medication judged by the investigator that could affect the trial"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "11", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664676", 
            "org_study_id": "U1111-1131-5236", 
            "secondary_id": "2012-003577-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Victoza"
            }, 
            {
                "arm_group_label": "Placebo-liraglutide", 
                "intervention_name": "Placebo-liraglutide", 
                "intervention_type": "Drug", 
                "other_name": "Isotonic saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucagon-Like Peptide 1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "liraglutide", 
            "victoza", 
            "GLP-1", 
            "kidney", 
            "diabetes", 
            "renal", 
            "diabetic nephropathy"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aarhus", 
                    "country": "Denmark", 
                    "zip": "8000"
                }, 
                "name": "Aarhus University Hospital, Department of Endocrinology and Diabetes"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients", 
        "overall_official": {
            "affiliation": "Aarhus University Hospital, Department of Endocrinology and Diabetes", 
            "last_name": "Jens S Christiansen, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Denmark: The Regional Committee on Biomedical Research Ethics", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Glomerular Filtration Rate (51Cr-EDTA plasma clearance)", 
            "safety_issue": "No", 
            "time_frame": "10-15 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664676"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Renal Blood Flow (functional magnetic resonance imaging)", 
                "safety_issue": "No", 
                "time_frame": "15 hours post-dose"
            }, 
            {
                "description": "Sodium, potassium, calcium, lithium and osmotically active substances.", 
                "measure": "Renal electrolyte clearance", 
                "safety_issue": "No", 
                "time_frame": "10-15 hours post-dose"
            }, 
            {
                "description": "Albumin, NGAL, KIM-1, angiotensinogen and 8-OHdG.", 
                "measure": "Excretion of kidney injury markers", 
                "safety_issue": "No", 
                "time_frame": "0-10 hours and 10-15 hours post-dose"
            }, 
            {
                "description": "Angiotensin II, renin, aldosterone, atrial natriuretic peptide, catecholamines.", 
                "measure": "Plasma concentrations of various hormones", 
                "safety_issue": "No", 
                "time_frame": "10-15 hours post-dose"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Novo Nordisk A/S", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "University of Copenhagen", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}